Loading clinical trials...
Loading clinical trials...
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orziloben (NST-6179) in Subjects With Intestinal Failure-Associated Liver Disease (IFALD)
Conditions
Interventions
NST-6179 Part A
NST-6179 Part B
+1 more
Locations
13
United States
Mayo Clinic Scottsdale Campus
Scottsdale, Arizona, United States
University of California San Francisco Medical Center
San Francisco, California, United States
MedStar Georgetown University Hospital
Washington D.C., District of Columbia, United States
Emory University School of Medicine
Atlanta, Georgia, United States
The University of Chicago Medical Center
Chicago, Illinois, United States
Boston Children's Hospital
Boston, Massachusetts, United States
Start Date
January 15, 2024
Primary Completion Date
June 30, 2025
Completion Date
June 30, 2025
Last Updated
January 7, 2025
Lead Sponsor
NorthSea Therapeutics B.V.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions